 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...3738394041424344454647...235236» |
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (clinicaltrials.gov) - Aug 21, 2023
P1, N=9, Active, not recruiting, Sponsor: Anne Noonan
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Jun 2023
- | Journal: Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? (Pubmed Central) - Aug 18, 2023
Chemotherapy regimens different from FOLFIRINOX and gemcitabine?+?nab-paclitaxel (OR 11.61 (2.53-53.36), p?=?0.002) and lymphovascular invasion (OR 11.28 (1.89-67.23), p?=?0.008) were associated to PR-3...A favorable PR is observed only in a limited number of cases. The prognostic role of PR, despite being promising, remains unclear and further multicentric studies are needed.
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial primary completion date: OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (clinicaltrials.gov) - Aug 18, 2023
P3, N=348, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
The prognostic role of PR, despite being promising, remains unclear and further multicentric studies are needed. Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Sep 2023 --> Sep 2025
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Aug 18, 2023
P2/3, N=1194, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Sep 2023 --> Sep 2025 Trial completion date: Jun 2023 --> Jun 2024
- || Vectibix (panitumumab) / Amgen
Enrollment closed, Trial primary completion date: OPTIPRIME: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (clinicaltrials.gov) - Aug 18, 2023
P2, N=118, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Jun 2023 --> Jun 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2022 --> Apr 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study. (Pubmed Central) - Aug 17, 2023
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2022 --> Apr 2024 Postoperatively, adjuvant therapy was associated with improved survival outcomes compared with non-adjuvant therapy after FOLFOX-HAIC-based conversion therapy among uHCC patients, especially for patients with macrovascular invasion and positive hepatitis B surface antigen.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Surgery, Metastases: Conversion surgery for advanced jejunal adenocarcinoma with multiple peritoneal metastases: a case report. (Pubmed Central) - Aug 17, 2023
Postoperatively, adjuvant therapy was associated with improved survival outcomes compared with non-adjuvant therapy after FOLFOX-HAIC-based conversion therapy among uHCC patients, especially for patients with macrovascular invasion and positive hepatitis B surface antigen. Although infrequent, conversion surgery may be a valid therapeutic option for selected cases of SBC with peritoneal metastasis.
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
P1/2 data, Clinical Trial,Phase II, Journal, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. (Pubmed Central) - Aug 17, 2023
P1/2
The combination of durvalumab-tremelimumab with mFOLFOX6 was tolerable with promising clinical activity in MSS mCRC. Clinicaltrials.gov identifier: NCT03202758 .
- | ondansetron / Generic mfg.
Trial completion date, Trial primary completion date: OPT-JIA: The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Aug 16, 2023
P=N/A, N=176, Recruiting, Sponsor: University of British Columbia
Clinicaltrials.gov identifier: NCT03202758 . Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
- || 5-fluorouracil / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study of Irinotecan Liposome in Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 16, 2023
P1, N=41, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Sep 2024 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: May 2023 --> Nov 2023
- |||| bemarituzumab (AMG 552) / Amgen
Trial completion date, Trial primary completion date, Metastases: FORTITUDE-101: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov) - Aug 15, 2023
P3, N=516, Recruiting, Sponsor: Amgen
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: May 2023 --> Nov 2023 Trial completion date: Oct 2026 --> Aug 2025 | Trial primary completion date: Oct 2026 --> Aug 2025
- || Ziihera (zanidatamab-hrii) / Jazz
Trial completion date, Trial primary completion date: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2023
P2, N=362, Recruiting, Sponsor: Jazz Pharmaceuticals
Trial completion date: Oct 2026 --> Aug 2025 | Trial primary completion date: Oct 2026 --> Aug 2025 Trial completion date: Apr 2024 --> Oct 2026 | Trial primary completion date: Mar 2023 --> Nov 2025
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov) - Aug 15, 2023
P=N/A, N=68, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Apr 2024 --> Oct 2026 | Trial primary completion date: Mar 2023 --> Nov 2025 Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2024
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial completion date, Trial primary completion date: A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 15, 2023
P2, N=21, Active, not recruiting, Sponsor: Shandong Cancer Hospital and Institute
Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Retrospective data, Journal: Oxaliplatin?induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy. (Pubmed Central) - Aug 14, 2023
Furthermore, the CAPOX regimen (OR: 2.831, 95% CI: 1.125-7.121; p?=?0.027), and higher post-treatment FIB-4 score (OR: 3.779; 95% CI:1.537- 9.294, p?=?0.004) were determined as independent risk factors for the increased SV. Our study revealed that increased SV had a significant association with higher FIB-4 score in patients treated with oxaliplatin-based chemotherapy.
- | Avastin (bevacizumab) / Roche
Journal, Metastases: Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment. (Pubmed Central) - Aug 14, 2023
Furthermore, FOLFOX-Bev treatment reset intercellular communication, which could potentially affect the function of non-cancer cells. Our findings provide valuable insights into the molecular mechanisms underlying the response of advanced CRC to FOLFOX-Bev treatment and highlight potential targets for improving the efficacy of this treatment strategy.
- | 5-fluorouracil / Generic mfg.
Journal: Hyperammonemia Secondary to 5-Fluorouracil. (Pubmed Central) - Aug 14, 2023
Upon admission, 5-FU was immediately discontinued and the patient was treated with lactulose enemas, intravenous fluids, rifaximin, and continuous renal replacement therapy with gradual recovery to baseline mental status. It is crucial for advanced practitioners to be aware of this rare side effect to ensure prompt diagnosis and maximize treatment effectiveness.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Journal: Can You Establish the Cause of This Patient's Shortness of Breath? (Pubmed Central) - Aug 14, 2023
He received front-line leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) and trastuzumab for 10 months before restaging imaging revealed progressive disease...He was discharged after an episode of pneumonia on a steroid taper with prophylactic trimethoprim/sulfamethoxazole...About a week later, wheezes were noticed on physical exam, and he was given a 5-day course of levofloxacin...He was discharged to an inpatient hospice facility where he passed away 2 weeks later. Drug-induced pneumonitis/ILD should be considered in all patients receiving trastuzumab deruxtecan who develop progressive shortness of breath or other respiratory complaints.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2023
P2, N=124, Active, not recruiting, Sponsor: Institut f
Drug-induced pneumonitis/ILD should be considered in all patients receiving trastuzumab deruxtecan who develop progressive shortness of breath or other respiratory complaints. Trial primary completion date: Apr 2023 --> Oct 2023
- || lunresertib (RP-6306) / Repare Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: MINOTAUR: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (clinicaltrials.gov) - Aug 14, 2023
P1, N=104, Recruiting, Sponsor: Repare Therapeutics
Trial primary completion date: Apr 2023 --> Oct 2023 Trial completion date: Dec 2024 --> Nov 2026 | Trial primary completion date: Jun 2023 --> Jul 2026
- || bemarituzumab (AMG 552) / Amgen
Trial completion date, Trial primary completion date: FORTITUDE-102: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (clinicaltrials.gov) - Aug 14, 2023
P1b, N=528, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2024 --> Nov 2026 | Trial primary completion date: Jun 2023 --> Jul 2026 Trial completion date:Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026
- || Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date: SPRINT: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=120, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Trial completion date:Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026 Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Aug 14, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Jun 2023 --> Mar 2024 Trial completion date: Jan 2029 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jan 2025
- | Enrollment change, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Aug 14, 2023
P2, N=229, Completed, Sponsor: Medical College of Wisconsin
Trial completion date: Jan 2029 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jan 2025 N=130 --> 229
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: FOLFIRINOX3 P: Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (clinicaltrials.gov) - Aug 14, 2023
P2, N=90, Not yet recruiting, Sponsor: Centre Georges Francois Leclerc
- |||| Tecentriq (atezolizumab) / Roche
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: DANTE: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (clinicaltrials.gov) - Aug 14, 2023
P2, N=674, Recruiting, Sponsor: Institut f
N=130 --> 229 Active, not recruiting --> Recruiting | N=295 --> 674 | Trial completion date: Oct 2025 --> Dec 2027 | Trial primary completion date: Oct 2025 --> May 2027
- | Metrexassist (TK-90) / Tosk
Enrollment closed, Trial completion date, Trial primary completion date: Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690 (clinicaltrials.gov) - Aug 14, 2023
P2a, N=24, Active, not recruiting, Sponsor: Tosk, Inc.
Active, not recruiting --> Recruiting | N=295 --> 674 | Trial completion date: Oct 2025 --> Dec 2027 | Trial primary completion date: Oct 2025 --> May 2027 Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- ||||| GRANITE / Gritstone bio
Enrollment closed, Combination therapy, Checkpoint inhibition, Checkpoint block, Metastases: GRANITE: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2023
P2/3, N=700, Active, not recruiting, Sponsor: Gritstone bio, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023 Recruiting --> Active, not recruiting
- ||| nisevokitug (NIS793) / Novartis
Enrollment closed: daNIS-3: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (clinicaltrials.gov) - Aug 14, 2023
P2, N=205, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| budigalimab (ABBV-181) / AbbVie, giloralimab (ABBV-927) / AbbVie
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Adverse events, Combination therapy, Metastases: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov) - Aug 14, 2023
P1b/2, N=40, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=129 --> 40 | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2024
- | elimusertib (BAY 1895344) / Bayer
Enrollment closed, Combination therapy, Metastases: Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (clinicaltrials.gov) - Aug 14, 2023
P1, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=129 --> 40 | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2024 Recruiting --> Active, not recruiting
- ||||||| 5-fluorouracil / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer (clinicaltrials.gov) - Aug 14, 2023
P3, N=298, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response. (Pubmed Central) - Aug 13, 2023
In colorectal cancer (CRC), the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic CRC...Thus, Immunoscore-IC could be a universal biomarker to predict response to PD-1/PD-L1 checkpoint inhibitor immunotherapy across multiple cancer indications. Therefore, cancer patient stratification (by Immunoscore-IC), based on the presence of T lymphocytes and PD-L1 potentially provides support for clinicians to guide them through combination cancer treatment decisions.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - Discussion () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_119;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_118;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_117;
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_92;
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_91;
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_90;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Session 18: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - Discussion () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_57;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Session 18: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_56;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Session 18: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_55;
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Session 9: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_29;
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Session 9: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_28;
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Session 9: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab () - Aug 12, 2023 - Abstract #GDUGINY2023GDU_GI_NY_27;
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy. (Pubmed Central) - Aug 12, 2023
Therefore, cancer patient stratification (by Immunoscore-IC), based on the presence of T lymphocytes and PD-L1 potentially provides support for clinicians to guide them through combination cancer treatment decisions. This study highlights the potential prognostic and predictive role of SMAD4 status in PDAC patients receiving FOLFIRINOX-based NAT.
- | Avastin (bevacizumab) / Roche
Journal, Metastases: Clinical benefits of FOLFOXIRI combined with bevacizumab for advanced-stage primary signet ring cell carcinoma of the appendix: A case report. (Pubmed Central) - Aug 10, 2023
This study highlights the potential prognostic and predictive role of SMAD4 status in PDAC patients receiving FOLFIRINOX-based NAT. The outcomes highlighted the importance of strict histopathologic assessment for appendiceal adenocarcinoma, and provided new ideas for the diagnosis and treatment of advanced-stage signet ring cell carcinoma of the appendix.
- || Onivyde (nanoliposomal irinotecan) / Ipsen
Trial primary completion date: SIRACUSA: A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (clinicaltrials.gov) - Aug 9, 2023
P1, N=122, Recruiting, Sponsor: Ipsen
The outcomes highlighted the importance of strict histopathologic assessment for appendiceal adenocarcinoma, and provided new ideas for the diagnosis and treatment of advanced-stage signet ring cell carcinoma of the appendix. Trial primary completion date: Jul 2023 --> Nov 2023
- | Trial initiation date: NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) (clinicaltrials.gov) - Aug 9, 2023
P3, N=609, Not yet recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Jul 2023 --> Nov 2023 Initiation date: Mar 2023 --> Sep 2023
- || ompenaclid (RGX-202) / Inspirna, EMD Serono
New P2 trial, Combination therapy, Metastases: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 9, 2023
P2, N=50, Not yet recruiting, Sponsor: Inspirna, Inc.